The Basis of Oncoimmunology

详细信息    查看全文

• 作者：A. Karolina Palucka¹ ; ² ; ^{karolina.palucka@jax.org" class="auth_mail" title="E-mail the corresponding author} ; Lisa M. Coussens³ ; ^{coussenl@ohsu.edu" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Cell
• 出版年：2016
• 出版时间：10 March 2016
• 年：2016
• 卷：164
• 期：6
• 页码：1233-1247
• 全文大小：1863 K

文摘

Cancer heterogeneity, a hallmark enabling clonal survival and therapy resistance, is shaped by active immune responses. Antigen-specific T cells can control cancer, as revealed clinically by immunotherapeutics such as adoptive T-cell transfer and checkpoint blockade. The host immune system is thus a powerful tool that, if better harnessed, could significantly enhance the efficacy of cytotoxic therapy and improve outcomes for cancer sufferers. To realize this vision, however, a number of research frontiers must be tackled. These include developing strategies for neutralizing tumor-promoting inflammation, broadening T-cell repertoires (via vaccination), and elucidating the mechanisms by which immune cells organize tumor microenvironments to regulate T-cell activity. Such efforts will pave the way for identifying new targets for combination therapies that overcome resistance to current treatments and promote long-term cancer control.